JNJ-95566692 enters phase 1, with Qilu neck and neck.
ApexOnco Front Page
Recent articles
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Mocertatug rezetecan is starting its first western pivotal trials.
The holiday period included Genmab’s discontinuation of acasunlimab.
A deal with Jacobio is worth $100m up front.
